Janux Therapeutics Lands Major Bristol Myers Squibb Collaboration, Up to $800M+ in Milestones
JANX sits 20% above its 52-week low of $12.12.
Summary
Janux Therapeutics announced a major collaboration with Bristol Myers Squibb, including $50 million upfront and up to $750 million in potential milestones, significantly bolstering its financial position and pipeline. The company also discontinued its JANX008 program to re-prioritize resources.
Key Events · M&A and Partnerships · JANX
-
Major Collaboration with Bristol Myers Squibb
Entered into an exclusive license and collaboration agreement with Bristol Myers Squibb (BMS) in January 2026 to develop a novel tumor-activated therapeutic for solid tumors.
-
Significant Financial Terms
Received an upfront payment of $15.0 million and a $35.0 million developmental milestone payment in March 2026, totaling $50.0 million in upfront/near-term payments. Eligible for up to $750.0 million in additional development, regulatory, and sales milestones, plus tiered royalties on global product sales.
-
Strategic Pipeline Reprioritization
Decided in April 2026 to voluntarily discontinue further clinical development of JANX008 (EGFR-targeted TRACTr program) to prioritize resources toward other pipeline opportunities, including the new BMS collaboration.
-
Strong Cash Position and Runway
Reported cash, cash equivalents, restricted cash, and short-term investments of $957.2 million as of March 31, 2026, providing a projected cash runway for at least 12 months.
Analysis · JANX · Life Sciences
Janux Therapeutics has secured a significant exclusive license and collaboration agreement with Bristol Myers Squibb (BMS), a major pharmaceutical company. This partnership is a substantial validation of Janux's proprietary technology platforms and provides a significant financial boost, including $50 million in upfront and near-term milestone payments, with potential for up to $750 million in additional development, regulatory, and sales milestones, plus tiered royalties. While the company reported a slight widening of its net loss and the discontinuation of its JANX008 program, the new collaboration revenue and strong cash position (over $957 million) provide a solid financial runway for at least 12 months. The strategic decision to discontinue JANX008 allows for a reprioritization of resources towards more promising pipeline candidates, including the newly partnered program with BMS.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JANX was trading at $14.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $884.5M. The 52-week trading range was $12.12 to $35.34. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.